Amgen Inc

Отворен

СекторЗдравеопазване

442.06 -0.4

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

440.49

Максимум

446.92

Ключови измерители

By Trading Economics

Приходи

-3.6B

-1.8B

Продажби

1.4B

10B

P/E

Средно за сектора

25.776

57.371

EPS

6.29

Дивидентна доходност

2.36

Марж на печалбата

-18.092

Служители

31,500

EBITDA

-416M

3.4B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

-11.06% downside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

2.36%

2.23%

Следващи печалби

3.11.2026 г.

Следваща дата на дивидент

11.09.2026 г.

Следваща дата на екс-дивидент

20.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

22B

226B

Предишно отваряне

442.46

Предишно затваряне

442.06

Настроения в новините

By Acuity

19%

81%

40 / 340 Класиране в Healthcare

Amgen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.08.2026 г., 23:51 ч. UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

21.08.2026 г., 20:06 ч. UTC

Event

Amgen Inc. went ex-dividend today, distributing $2.52 per share, as shares trade higher since Thursday's close amid a strong broader market.

20.08.2026 г., 23:21 ч. UTC

Amgen Inc. shares are lower in after-market trading, with no specific news identified. Rising U.S. Treasury yields contribute to broader market pressure.

19.08.2026 г., 22:56 ч. UTC

Amgen Inc. shares declined slightly in after-hours trading, reflecting a minor decrease since Wednesday's close. The stock remains well above its 20-day moving average.

18.08.2026 г., 23:26 ч. UTC

Amgen Inc shares are higher during after-market hours, maintaining a strong position above its 20-day moving average despite broader market pressures.

17.08.2026 г., 22:01 ч. UTC

Amgen Inc shares are trading lower in after-market hours. Broader market volatility, influenced by rising crude oil prices, may be affecting investor sentiment.

14.08.2026 г., 19:46 ч. UTC

News

Amgen shares are lower today despite Barclays raising the price target to $380, influenced by a decline in U.S. retail sales for July.

13.08.2026 г., 20:06 ч. UTC

News

Amgen Inc reported second-quarter revenue of $10.05 billion, exceeding expectations. The company raised its full-year revenue and EPS guidance, contributing to shares moving higher.

12.08.2026 г., 19:56 ч. UTC

News

Amgen Inc plans to open a new Science and Innovation Center in Hyderabad by 2027, enhancing its global R&D network. Shares are gaining today.

11.08.2026 г., 19:41 ч. UTC

Social Media
News

Amgen Inc shares declined during Tuesday's session after peaking earlier. The stock remains above its 20-day moving average amid social media discussions on its long-term trajectory.

7.08.2026 г., 19:22 ч. UTC

News

Amgen Inc shares are higher, supported by strong Q2 results and positive guidance revisions. The Biotechnology sub-sector is also advancing today.

6.08.2026 г., 19:56 ч. UTC

Social Media
News

Amgen shares are lower today despite a price target increase from Bernstein. The stock reached a session high before retracing to midday lows.

5.08.2026 г., 19:52 ч. UTC

Social Media
News

Amgen Inc. shares advanced following strong Q2 earnings and raised revenue guidance. Analysts from TD Cowen and Scotiabank maintained "Buy" ratings with high price targets.

4.08.2026 г., 23:02 ч. UTC

Social Media
News

Amgen reported strong Q2 results but shares are lower in after-market hours amid rising expense forecasts and the discontinuation of obesity candidate AMG 513.

3.08.2026 г., 23:01 ч. UTC

Amgen Inc. shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

31.07.2026 г., 20:07 ч. UTC

News

Amgen's Board declared a quarterly dividend of $2.52 per share, while shares are trading lower amid rising Treasury yields and inflation concerns.

30.07.2026 г., 21:32 ч. UTC

News

Amgen Inc announced a quarterly dividend of $2.52 per share, but shares are lower in after-market trading following mixed tech sector earnings.

29.07.2026 г., 23:26 ч. UTC

Amgen Inc. shares traded roughly flat after-market, remaining above the 20-day moving average amid broader market volatility following the Federal Reserve's interest rate decision.

28.07.2026 г., 20:02 ч. UTC

Social Media

Amgen Inc. shares are advancing, reaching an all-time high following the acquisition of Horizon, which enhances its focus on rare diseases and strategic growth areas.

27.07.2026 г., 23:22 ч. UTC

Amgen Inc shares are higher in after-market hours, reaching a peak late in the session. Broader market sentiment remains positive amid reduced oil supply concerns.

24.07.2026 г., 23:31 ч. UTC

Amgen Inc shares are higher in after-market trading, nearing the upper end of their one-month range. No specific news was identified to explain the movement.

23.07.2026 г., 23:26 ч. UTC

News

Amgen Inc shares traded lower in after-market hours amid challenges in the biotechnology sector and increased credit risk perceptions in the investment-grade bond market.

22.07.2026 г., 23:11 ч. UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and positioning above its 20-day moving average.

21.07.2026 г., 23:46 ч. UTC

Amgen Inc shares are lower in after-market hours, reflecting a modest recovery from earlier losses. No specific news was identified to explain the movement.

20.07.2026 г., 19:56 ч. UTC

Social Media

Amgen Inc. shares are lower today, reflecting broader market trends amid geopolitical tensions and inflation concerns. The stock ranks fourth in the SCHD ETF.

17.07.2026 г., 20:02 ч. UTC

Macro Event

Amgen Inc. shares are lower during Friday's session, despite a rise in the Michigan Consumer Sentiment Index to 54.4 in July.

16.07.2026 г., 18:02 ч. UTC

Amgen Inc. shares are higher today, diverging from broader market declines amid rising crude oil prices and geopolitical tensions. No specific news was identified.

15.07.2026 г., 19:16 ч. UTC

Amgen Inc shares are higher Wednesday, reflecting a positive market trend amid investor interest in biotechnology despite geopolitical tensions affecting the bond market.

14.07.2026 г., 19:16 ч. UTC

News
Macro Event

Amgen Inc. shares are lower amid pressure from recent product recalls due to quality control issues, impacting its reputation and operational efficiency.

13.07.2026 г., 19:46 ч. UTC

News

Shares lower today despite price target increases from Guggenheim, UBS.

Сравнение с други в отрасъла

Ценова промяна

Amgen Inc Прогноза

Ценова цел

By TipRanks

-11.06% надолу

12-месечна прогноза

Среден 394.73 USD  -11.06%

Висок 460 USD

Нисък 230 USD

Според 23 анализатори от Wall Street, предложили 12-месечна ценова цел за Amgen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

23 ratings

10

Купи

11

Задържане

2

Продай

Настроение

By Acuity

40 / 340 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat